San Diego-based mostly Viking Therapeutics marked itself as a significant competitor inside the weight loss drug market place in February following revealing promising details from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection As well as in March